QX027N
/ Qyuns Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 13, 2025
LONG-ACTING BISPECIFIC ANTIBODY QX027N OBTAINS TWO CLINICAL TRIAL APPROVALS
(HKEXnews)
- "...Approvals from the Center for Drug Evaluation of the National Medical Products Administration (Acceptance Nos.: CXSL2500757, CXSL2500758), intended for the treatment of asthma and atopic dermatitis."
New trial • Asthma • Atopic Dermatitis • Immunology
1 to 1
Of
1
Go to page
1